Jacek Postepski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jacek Postepski has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Agnieszka Korobowicz
1 shared publicationEdyta Olesińska
Department of Pediatric Lung Diseases and Rheumatology, Medical University of Lublin, Lublin, Poland
1 shared publicationEwa Tuszkiewicz-Misztal
1 shared publicationKatarzyna Kobusińska
Cardiology and Rheumatology with Neonatal Pathology Unit, Department of Pediatrics, District Pediatric Hospital of J. Brudziński, Bydgoszcz, Poland
1 shared publicationMaria Kozioł-Montewka
1 shared publicationVioletta Opoka-Winiarska
1 shared publication
Latest Publications
- Open Access
- 21 July 2012
- Published by Springer Nature in Rheumatology International
- Vol. 33 (10) , 2657-2660
Clinical remission in juvenile idiopathic arthritis after termination of etanercept
Biologicals are very effective for inhibiting disease progression in active juvenile idiopathic arthritis (JIA). To date, there have been no recommendations on how and when to stop therapy with TNF inhibitors. Our objective was to analyze characteristics and the disease course of JIA patients who discontinued etanercept due to achievement of inactive disease. Data of 39 patients with JIA from two clinical pediatric rheumatology centers in Bydgoszcz and Lublin (Poland) were analyzed retrospectively. All patients discontinued etanercept due to a remission on treatment. Etanercept was started after a mean 33.7 ± 36 (range 3–137) months of disease. The mean duration of therapy with etanercept was 34.7 ± 16.7 (range 6–72) months, with a mean duration of remission on medication 21.3 ± 9.6 (range 4–42) months before withdrawal of etanercept. The mean duration of remission after etanercept discontinuation was 14.2 ± 12.1 (range of 1–60) months. Only 12/39 (30.8 %) patients did not develop a disease exacerbation until the end of the study. Early flares, that is less than 6 months after termination of etanercept, were observed in 15/39 (38.5 %) patients. Twelve (30.8 %) patients restarted etanercept after exacerbation—all patients responded satisfactorily. Our data show that etanercept discontinuation in a substantial proportion of JIA patients results in early disease exacerbation. In many cases, reintroduction of etanercept is needed. Patients, in whom etanercept was restarted, responded satisfactorily.
- 21 July 2012
- Published by Springer Nature in Rheumatology International
- Vol. 33 (10) , 2657-2660
Open AccessClinical remission in juvenile idiopathic arthritis after termination of etanercept
Biologicals are very effective for inhibiting disease progression in active juvenile idiopathic arthritis (JIA). To date, there have been no recommendations on how and when to stop therapy with TNF inhibitors. Our objective was to analyze characteristics and the disease course of JIA patients who discontinued etanercept due to achievement of inactive disease. Data of 39 patients with JIA from two clinical pediatric rheumatology centers in Bydgoszcz and Lublin (Poland) were analyzed retrospectively. All patients discontinued etanercept due to a remission on treatment. Etanercept was started after a mean 33.7 ± 36 (range 3–137) months of disease. The mean duration of therapy with etanercept was 34.7 ± 16.7 (range 6–72) months, with a mean duration of remission on medication 21.3 ± 9.6 (range 4–42) months before withdrawal of etanercept. The mean duration of remission after etanercept discontinuation was 14.2 ± 12.1 (range of 1–60) months. Only 12/39 (30.8 %) patients did not develop a disease exacerbation until the end of the study. Early flares, that is less than 6 months after termination of etanercept, were observed in 15/39 (38.5 %) patients. Twelve (30.8 %) patients restarted etanercept after exacerbation—all patients responded satisfactorily. Our data show that etanercept discontinuation in a substantial proportion of JIA patients results in early disease exacerbation. In many cases, reintroduction of etanercept is needed. Patients, in whom etanercept was restarted, responded satisfactorily.
- 25 July 2003
- Vol. 7 (2)
[Role of mycoplasma pneumoniae infection in aetiopathogenesis of juvenile idiopatic arthritis].
Although more and more is known about chronic autoimmune diseases, attempts to establish one trigger factor have been unsuccessful. The role of endogenic factors is beyond doubt. But it is emphasized that environmental factors are necessary to cause the disease. Infections are taken under consideration as trigger mechanism in the development of autoimmune diseases including chronic arthritis. Both numerous viruses and bacteria are among the microorganism mentioned. We considered it sensible to conduct research on Mycoplasma pneumoniae infections in a group of patients with juvenile idiopathic arthritis (JIA).
- 25 July 2003
- Vol. 7 (2)
[Role of mycoplasma pneumoniae infection in aetiopathogenesis of juvenile idiopatic arthritis].
Although more and more is known about chronic autoimmune diseases, attempts to establish one trigger factor have been unsuccessful. The role of endogenic factors is beyond doubt. But it is emphasized that environmental factors are necessary to cause the disease. Infections are taken under consideration as trigger mechanism in the development of autoimmune diseases including chronic arthritis. Both numerous viruses and bacteria are among the microorganism mentioned. We considered it sensible to conduct research on Mycoplasma pneumoniae infections in a group of patients with juvenile idiopathic arthritis (JIA).